Monthly Archives: September 2009
Biosimilars: How the EMEA Got it Right (Part 2, the Science)
In the first part of this series, we looked at where the EMEA (the EU equivalent of the FDA) got it right in terms of the regulatory pathway to biosimilars, without putting patients at risk. Their process is rigorous, testing … Continue reading
